Literature DB >> 9488406

Endotoxin binding and elimination by monocytes: secretion of soluble CD14 represents an inducible mechanism counteracting reduced expression of membrane CD14 in patients with sepsis and in a patient with paroxysmal nocturnal hemoglobinuria.

N Hiki1, D Berger, C Prigl, E Boelke, H Wiedeck, M Seidelmann, L Staib, M Kaminishi, T Oohara, H G Beger.   

Abstract

Little is known about the role of peripheral blood mononuclear cells (PBMCs) in lipopolysaccharide (LPS) elimination. We studied the endotoxin elimination capacities (EEC) of PBMCs of 15 healthy volunteers, 13 patients with sepsis, and 1 patient suffering from paroxysmal nocturnal hemoglobinuria (PNH). Although expression of CD14, the best-characterized receptor for LPS to date, was reduced from 93.6% +/- 0.8% in healthy subjects to 50.5% +/- 6.5% in patients with sepsis and was 0.3% in a patient with septic PNH, EEC were found to be unchanged. There was no difference in the amount of tumor necrosis factor alpha (TNF-alpha) released by PBMCs of healthy donors and patients with sepsis. Anti-CD14 antibodies (MEM-18) completely suppressed EEC, binding of fluorescein isothiocyanate-labeled LPS to monocytes as determined by FACScan analysis, and TNF-alpha release in all three groups studied. The concentrations of soluble CD14 (sCD14) secreted by endotoxin-stimulated PBMCs from healthy donors and patients with sepsis amounted to 4.5 +/- 0.4 and 20.1 +/- 1.8 ng/ml, respectively. Based on our results, we suggest that PBMCs eliminate LPS by at least two different mechanisms; in healthy subjects, the membrane CD14 (mCD14) receptor is the most important factor for LPS elimination, while in patients with sepsis (including the septic state of PNH), increased sCD14 participates in LPS elimination. Secretion of sCD14 is strongly enhanced under conditions of low expression of mCD14 in order to counteract the reduction of mCD14 and maintain the function of monocytes. This sCD14 may substitute the role of mCD14 in LPS elimination during sepsis. The elimination of LPS by PBMCs correlates with the binding reaction and the secretion of TNF-alpha.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9488406      PMCID: PMC108026          DOI: 10.1128/IAI.66.3.1135-1141.1998

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  56 in total

1.  Binding, internalization, and deacylation of bacterial lipopolysaccharide by human neutrophils.

Authors:  M Luchi; R S Munford
Journal:  J Immunol       Date:  1993-07-15       Impact factor: 5.422

2.  Short time exposure to lipopolysaccharide is sufficient to activate human monocytes.

Authors:  P Gallay; C V Jongeneel; C Barras; M Burnier; J D Baumgartner; M P Glauser; D Heumann
Journal:  J Immunol       Date:  1993-06-01       Impact factor: 5.422

3.  Enhanced production of LPS-induced cytokines during differentiation of human monocytes to macrophages. Role of LPS receptors.

Authors:  S Gessani; U Testa; B Varano; P Di Marzio; P Borghi; L Conti; T Barberi; E Tritarelli; R Martucci; D Seripa
Journal:  J Immunol       Date:  1993-10-01       Impact factor: 5.422

4.  Mechanisms of cytokine cascade activation in patients with sepsis: normal cytokine transcription despite reduced CD14 receptor expression.

Authors:  W Ertel; F Krombach; J P Kremer; D Jarrar; V Thiele; J Eymann; S Muenzing; E Faist; K Messmer; F W Schildberg
Journal:  Surgery       Date:  1993-08       Impact factor: 3.982

5.  Altered leukocyte immunophenotypes in septic shock. Studies of HLA-DR, CD11b, CD14, and IL-2R expression.

Authors:  R Y Lin; M E Astiz; J C Saxon; E C Rackow
Journal:  Chest       Date:  1993-09       Impact factor: 9.410

6.  Endotoxin-neutralizing capacity of soluble CD14 is a highly conserved specific function.

Authors:  U Grunwald; C Krüger; C Schütt
Journal:  Circ Shock       Date:  1993-03

7.  Impaired phagocyte responses to lipopolysaccharide in paroxysmal nocturnal hemoglobinuria.

Authors:  J Duchow; A Marchant; A Crusiaux; C Husson; C Alonso-Vega; D De Groote; P Neve; M Goldman
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

8.  The novel subset of CD14+/CD16+ blood monocytes is expanded in sepsis patients.

Authors:  G Fingerle; A Pforte; B Passlick; M Blumenstein; M Ströbel; H W Ziegler-Heitbrock
Journal:  Blood       Date:  1993-11-15       Impact factor: 22.113

9.  Prevention of endotoxin-induced monokine release by human low- and high-density lipoproteins and by apolipoprotein A-I.

Authors:  W A Flegel; M W Baumstark; C Weinstock; A Berg; H Northoff
Journal:  Infect Immun       Date:  1993-12       Impact factor: 3.441

10.  Anti-endotoxin monoclonal antibodies inhibit secretion of tumor necrosis factor-alpha by two distinct mechanisms.

Authors:  R S Burd; R J Battafarano; C S Cody; M S Farber; C A Ratz; D L Dunn
Journal:  Ann Surg       Date:  1993-09       Impact factor: 12.969

View more
  23 in total

1.  Increased levels of circulating soluble CD14 in Kawasaki disease.

Authors:  S Takeshita; K Nakatani; H Tsujimoto; Y Kawamura; H Kawase; I Sekine
Journal:  Clin Exp Immunol       Date:  2000-02       Impact factor: 4.330

2.  Dysfunctional B-cell activation in cirrhosis resulting from hepatitis C infection associated with disappearance of CD27-positive B-cell population.

Authors:  Hiroyoshi Doi; Tara K Iyer; Erica Carpenter; Hong Li; Kyong-Mi Chang; Robert H Vonderheide; David E Kaplan
Journal:  Hepatology       Date:  2012-01-19       Impact factor: 17.425

3.  Changes in endotoxin-binding proteins during major elective surgery: important role for soluble CD14 in regulation of biological activity of systemic endotoxin.

Authors:  N Hiki; D Berger; M A Dentener; Y Mimura; W A Buurman; C Prigl; M Seidelmann; E Tsuji; M Kaminishi; H G Beger
Journal:  Clin Diagn Lab Immunol       Date:  1999-11

4.  Plasma levels of soluble CD14 independently predict mortality in HIV infection.

Authors:  Netanya G Sandler; Handan Wand; Annelys Roque; Matthew Law; Martha C Nason; Daniel E Nixon; Court Pedersen; Kiat Ruxrungtham; Sharon R Lewin; Sean Emery; James D Neaton; Jason M Brenchley; Steven G Deeks; Irini Sereti; Daniel C Douek
Journal:  J Infect Dis       Date:  2011-01-20       Impact factor: 5.226

5.  Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection.

Authors:  Netanya G Sandler; Christopher Koh; Annelys Roque; Jason L Eccleston; Rebecca B Siegel; Mary Demino; David E Kleiner; Steven G Deeks; T Jake Liang; Theo Heller; Daniel C Douek
Journal:  Gastroenterology       Date:  2011-07-02       Impact factor: 22.682

6.  Chronic Hepatitis C Virus Infection and the Proinflammatory Effects of Injection Drug Use.

Authors:  Martin Markowitz; Sherry Deren; Charles Cleland; Melissa La Mar; Evelyn Silva; Pedro Batista; Leslie St Bernard; Natanya Gettie; Kristina Rodriguez; Teresa H Evering; Haekyung Lee; Saurabh Mehandru
Journal:  J Infect Dis       Date:  2016-08-11       Impact factor: 5.226

Review 7.  Microbial translocation in HIV infection: causes, consequences and treatment opportunities.

Authors:  Netanya G Sandler; Daniel C Douek
Journal:  Nat Rev Microbiol       Date:  2012-08-13       Impact factor: 60.633

8.  Chronic immune activation in common variable immunodeficiency (CVID) is associated with elevated serum levels of soluble CD14 and CD25 but not endotoxaemia.

Authors:  J Litzman; J Nechvatalova; J Xu; O Ticha; M Vlkova; Z Hel
Journal:  Clin Exp Immunol       Date:  2012-12       Impact factor: 4.330

9.  Liver injury is associated with mortality in sickle cell disease.

Authors:  J J Feld; G J Kato; C Koh; T Shields; M Hildesheim; D E Kleiner; J G Taylor; N G Sandler; D Douek; V Haynes-Williams; J S Nichols; J H Hoofnagle; T Jake Liang; M T Gladwin; T Heller
Journal:  Aliment Pharmacol Ther       Date:  2015-08-03       Impact factor: 8.171

10.  Brief Report: CD14brightCD16- monocytes and sCD14 level negatively associate with CD4-memory T-cell frequency and predict HCV-decline on therapy.

Authors:  Chelsey J Judge; Johan K Sandberg; Nicholas T Funderburg; Kenneth E Sherman; Adeel A Butt; Minhee Kang; Alan L Landay; Michael M Lederman; Donald D Anthony
Journal:  J Acquir Immune Defic Syndr       Date:  2016-11-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.